Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma

  • Authors:
    • Tetsuo Fujita
    • Takahiro Hirayama
    • Daisuke Ishii
    • Kazumasa Matsumoto
    • Kazunari Yoshida
    • Masatsugu Iwamura
  • View Affiliations

  • Published online on: July 26, 2018     https://doi.org/10.3892/mco.2018.1684
  • Pages: 394-398
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Elderly individuals represent a consistent proportion of all cancer patients. However, they are under-represented in clinical trials. The present study evaluated the actual tolerability of sunitinib in elderly Japanese patients with advanced renal cell carcinoma (RCC). A total of 56 consecutive patients with advanced RCC treated with sunitinib were enrolled. Patients were divided into two groups according to their age at the time of sunitinib initiation: i) elderly cohort (≥70 years); and ii) younger cohort (<70 years). Disease control rate, progression-free survival, overall survival and relative dose intensity (RDI) were compared between the two cohorts. The elderly cohort comprised of 14 patients (25.0%), and the younger cohort included 42 patients (75.0%). The elderly cohort had a significantly higher Charlson comorbidity index than the younger cohort (mean, 9.7 vs. 7.9; P<0.0001). Disease control rate, progression-free survival, and overall survival were not significantly different. The elderly cohort had a significantly lower RDI than the younger cohort (mean, 51.7 vs. 65.0%; P=0.0340). Thus, treatment with sunitinib is feasible and effective in elderly Japanese patients with advanced RCC. However, the RDI of elderly patients was significantly lower, and a relatively low dose of sunitinib provided optimal therapeutic efficacy.
View Figures
View References

Related Articles

Journal Cover

October 2018
Volume 9 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Fujita, T., Hirayama, T., Ishii, D., Matsumoto, K., Yoshida, K., & Iwamura, M. (2018). Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma. Molecular and Clinical Oncology, 9, 394-398. https://doi.org/10.3892/mco.2018.1684
MLA
Fujita, T., Hirayama, T., Ishii, D., Matsumoto, K., Yoshida, K., Iwamura, M."Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma". Molecular and Clinical Oncology 9.4 (2018): 394-398.
Chicago
Fujita, T., Hirayama, T., Ishii, D., Matsumoto, K., Yoshida, K., Iwamura, M."Efficacy and safety of sunitinib in elderly patients with advanced renal cell carcinoma". Molecular and Clinical Oncology 9, no. 4 (2018): 394-398. https://doi.org/10.3892/mco.2018.1684